14.10.19: Not intended for U.S. and UK Media

U.S. FDA approves rivaroxaban to help prevent blood clots in acutely ill medical patientsA new oral option for patients in the U.S. with acute medical illnesses at risk for thromboembolic complications who are not at high risk of bleeding / Rivaroxaban is the only non vitamin K antagonist oral anticoagulant (NOAC) approved in the U.S for the continuum of venous thromboembolism (VTE) care, from prevention and treatment of initial VTE through extended prevention of recurrent VTEmehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news